Gedea Biotech granted European Patent for the formulation of its vaginal pHyph tablet for women with vaginal infections
Further strengthens Gedea Biotech’s broad patent portfolio pHyph has demonstrated a superior safety profile, a cure rate in line with antibiotics and a lower infection recurrence rate Additionally, unlike antibiotics, pHyph will not promote antimicrobial resistance Lund, Sweden, September…
